- Home
- TSHA vs KIND Comparison
TSHA vs KIND Comparison
Compare TSHA & KIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- KIND
- Stock Information
- Founded
- TSHA 2019
- KIND 2011
- Country
- TSHA United States
- KIND United States
- Employees
- TSHA N/A
- KIND N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- KIND Computer Software: Programming Data Processing
- Sector
- TSHA Health Care
- KIND Technology
- Exchange
- TSHA Nasdaq
- KIND Nasdaq
- Market Cap
- TSHA 728.4M
- KIND 608.3M
- IPO Year
- TSHA 2020
- KIND N/A
- Fundamental
- Price
- TSHA $2.65
- KIND $1.88
- Analyst Decision
- TSHA Strong Buy
- KIND Buy
- Analyst Count
- TSHA 6
- KIND 4
- Target Price
- TSHA $8.17
- KIND $2.56
- AVG Volume (30 Days)
- TSHA 2.6M
- KIND 2.3M
- Earning Date
- TSHA 08-11-2025
- KIND 08-07-2025
- Dividend Yield
- TSHA N/A
- KIND N/A
- EPS Growth
- TSHA N/A
- KIND N/A
- EPS
- TSHA N/A
- KIND N/A
- Revenue
- TSHA $7,224,000.00
- KIND $248,306,000.00
- Revenue This Year
- TSHA N/A
- KIND $1.66
- Revenue Next Year
- TSHA N/A
- KIND $10.87
- P/E Ratio
- TSHA N/A
- KIND N/A
- Revenue Growth
- TSHA N/A
- KIND 12.01
- 52 Week Low
- TSHA $1.05
- KIND $1.32
- 52 Week High
- TSHA $3.31
- KIND $3.00
- Technical
- Relative Strength Index (RSI)
- TSHA 56.06
- KIND 60.19
- Support Level
- TSHA $2.34
- KIND $1.63
- Resistance Level
- TSHA $2.81
- KIND $2.50
- Average True Range (ATR)
- TSHA 0.16
- KIND 0.13
- MACD
- TSHA 0.01
- KIND 0.02
- Stochastic Oscillator
- TSHA 67.37
- KIND 31.11
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About KIND Nextdoor Holdings Inc.
Nextdoor Holdings Inc is the platform to connect to the neighborhoods. The purpose is to cultivate a kinder world where everyone has a neighborhood. Neighbors around the world turn to Nextdoor daily to receive trusted information, give and get help, get things done, and build real-world connections with nearby neighbors, businesses, and public services. It offers a comprehensive suite of advertising solutions designed to deliver exceptional value for businesses of all size.